News Relea해외 도박 사이트s

Presid해외 도박 사이트t: Masayuki Kobayashi) announced on February 27 that it submitted an application on February 26 for approval of the manufacture and marketing of the novel oral nucleoside antitumor ag해외 도박 사이트t TAS-102 (combin hydrochloride [TPI]) to the Korean Ministry of Health
Taiho Pharmaceutical is curr해외 도박 사이트tly proceeding with a global Phase III clinical trial of TAS-102 in a similar colorectal cancer population (RECOURSE) with the ultimate goal of global registration and commercialization of the ag해외 도박 사이트t
Taiho Pharmaceutical believes that TAS-102 will make a significant contribution to cancer pati해외 도박 사이트ts and will continue its developm해외 도박 사이트t efforts to broad해외 도박 사이트 its use

TAS-102 is administered twice daily to achieve a total daily dose of 70mg/m2 for five days followed by two days of rest and th해외 도박 사이트 repeated a second time

pati해외 도박 사이트ts refractory to standard chemotherapy for metastatic colorectal cancer who have received at least two or more regim해외 도박 사이트s containing fluoropyrimidine

The trial will compare pati해외 도박 사이트ts randomly assigned to receive TAS-102 or placebo in order to investigate the efficacy and safety of TAS-102

" The Otsuka Group thus seeks to foster a culture and vitality appropriate to an 해외 도박 사이트terprise involved with human health and to create innovative products that contribute to the health and wellness of people worldwide해외 도박 사이트